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Objectives: Recent studies have recognized that signs of 
functional disability in schizophrenia are evident in early 
phases of the disorder, and, as a result, can potentially 
serve as vulnerability markers of future illness. However, 
functional measures in the psychosis prodrome have focused 
exclusively on real-world achievements, rather than on the 
skills required to carry-out a particular real-world func-
tion (ie, capacity). Despite growing evidence that dimin-
ished capacity is critical to the etiology of the established 
disorder, virtually no attention has been directed towards 
assessing functional capacity in the pre-illness stages. In 
the present study, we introduce the Map task, a measure 
to assess functional capacity in adolescent and young-
adult high-risk populations. Methods: The Map task was 
administered to 609 subjects at Clinical High-Risk (CHR) 
for psychosis and 242 Healthy Controls (HCs) participat-
ing in the North American Prodrome Longitudinal Study 
(NAPLS2). Subjects were required to efficiently complete 
a set of specified errands in a fictional town. Results: CHR 
participants showed large impairments across major indi-
ces of the Map task, relative to the HCs. Most impor-
tantly, poor performance on the Map task significantly 
predicted conversion to psychosis, even after adjusting 
for age, IQ, clinical state, and other potential confound-
ers. Conclusions: To the best of our knowledge, the Map 
task is one of the first laboratory-based measures to assess 
functional capacity in high-risk populations. Functional 
capacity deficits prior to the onset of psychosis may reflect 
a basic mechanism that underlies risk for psychosis. Early 
intervention targeting this domain may help to offset risk 
and independently improve long-term outcome.
Key words:  prodromal/role functioning/disability/ 
prediction/CHR/NAPLS
Introduction
Functional disability is now a well-established compo-
nent of chronic psychotic disorders, especially schizo-
phrenia, and represents a major health concern in its 
own right.1–3 A complex construct, functional disability 
generally refers to an inability to be independently self-
sustaining in the community. Especially when combined 
with social isolation, as is often the case, functional dis-
ability is highly resistant to treatment even when the more 
dramatic positive symptoms markedly improve with 
treatment. It has only been recently recognized that signs 
of functional disability are evident prior to the onset of 
psychosis, and are not wholly caused by emerging illness. 
As a result, early impaired functioning may represent a 
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new class of vulnerability indicators of future psychosis,2 
previously unstudied and most likely complementary to 
neurocognitive predictors.4
In prodromal research targeting pre-illness youth at 
risk, achievement has been measured in several projects 
using the Global Functioning: Social (GF:S) and Role 
(GF:R) scales, and early social deficits in particular, 
appear to be predictors of future illness.5–7 The 2 matched 
scales are clinical measures reflecting real-world func-
tioning as reported by patients and/or relatives.8 Several 
recent studies have reported that social skills appear to 
be biologically related traits9–11 associated with increased 
vulnerability to the development of psychosis11–18 and 
are a major component of functional disability.14,19 Role 
functioning in prodromal individuals has been measured 
in terms of adjustment to school in adolescents and to 
early employment in older individuals. While impaired 
role (school/employment) functioning has not been as 
predictive of psychosis as social functioning,13,20–22 role 
deficits have been shown to be core aspects of long-term 
disability.23 In some cases, role functioning appears to be 
highly susceptible to environmental determinants, such 
as economic factors and access to educational resources.24
Due to the variability in role achievement, functional 
capacity may be a more valid predictor of psychosis at 
this phase of illness. The distinction between functional 
capacity vs achievement, 2 major components of func-
tional disability, is particularly salient to the vulnerability 
issue. “Capacity” refers to one’s true ability to perform in 
the real world and “achievement,” to the extent to which 
capacity is translated into real-world accomplishments.25 
Patients with chronic psychosis have been found to be 
highly impaired in both achievement and capacity.26 Of the 
2 constructs, achievement is the more quantifiable and is 
typically measured using attainment of real life milestones 
or accomplishments.27 Functional capacity, on the other 
hand, is a more abstract construct referring to the actual 
ability to sustainably adapt to the demands of society. 
Capacity measures typically involve standardized paper 
and pencil assessments in a laboratory setting that simu-
late limited but real-world scenarios.28 While chronically ill 
adult patients have been shown to have major impairments 
in both capacity and achievement, this is less clear for indi-
viduals at Clinical High-Risk (CHR) for psychosis.
However, despite substantial evidence that diminished 
capacity is a key barrier to good functional outcomes in 
adult patients with schizophrenia, virtually no attention 
has been directed towards capacity in the pre-illness stages 
or the extent to which deficits in capacity precede or parallel 
the decline in achievement often reported during the prodro-
mal stage.29 Although several functional capacity measures 
have been developed, eg, the UCSD Performance-Based 
Skills Assessment (UPSA30–33), they are designed to test 
adult skill sets in highly impaired chronically ill schizophre-
nia or bipolar patients, and are not appropriate for younger 
at-risk individuals either in content or difficulty level.
To address this gap in prodromal research, we sought 
to develop a laboratory-based measure analogous to 
role capacity measures used with chronic adult patients, 
but that addressed skills much more complex than those 
characteristically assessed in florid patients. The task had 
to go beyond school performance to determine if  an indi-
vidual is able to conduct basic everyday tasks. The result-
ing Map task, unlike existing role capacity measures, is 
free of potential confounds such as social interaction and 
does not require mastery of any adult level tasks (ie, check 
writing, money management) making it age-appropriate 
for adolescents. It can be administered and scored eas-
ily and reliably and is suitable for use with less impaired 
at-risk adolescents and young adults. The Map task was 
inspired by errand-planning tasks developed for the 
Office of Naval Research to study planning processes34 
that were later adapted for use with children.35,36 The task 
requires participants to complete a list of errands in a 
timely and efficient manner stressing the ability to simul-
taneously process multiple instructions, thus measuring 
a narrowly defined set of specific skills required to carry 
out a particular real-world function, in this case, the abil-
ity to complete a set of errands on a shopping trip.
The goals of the current study were to evaluate the 
validity of the Map task as a new risk factor for psy-
chosis that reflects functioning rather than clinical com-
ponents of illness. Specific goals of the study were to: 
(1) Determine whether CHR individuals show impair-
ments on the Map task compared to Healthy Controls 
(HCs); (2) Determine whether poor performance on the 
Map task is predictive of conversion to psychosis and; 
(3) Establish that the predictive association between 
impaired functional capacity as measured by the Map 
task and psychosis is independent of the contributions 
of other potentially explanatory variables such as intel-
lectual deficits, clinical symptoms, and role achievement.
Materials and Methods
Sample Description
Data was collected as part of the larger North American 
Prodrome Longitudinal Study (NAPLS2) sample 
(N = 1044), a multisite prospective study that is funded by 
the National Institute of Mental Health.37 The NAPLS2 
sample consists of 764 CHR subjects and 280 HC par-
ticipants. Subjects were collected at the 8 NAPLS2 
sites located at Emory University, Harvard University, 
University of Calgary, UCLA, UCSD, UNC at Chapel 
Hill, Yale University, and the Zucker Hillside Hospital in 
New York. Recruitment efforts varied at the 8 sites and 
primarily resulted from direct referrals, referrals from 
community professionals, and direct advertising in the 
community and on the internet.38
Participants were identified as CHR based on criteria 
derived from the Scale of Prodromal Symptoms (SOPS39–41). 
Inclusion criteria were based on one of the following: 
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(1) attenuated positive symptoms (APS), defined by the 
onset or worsening in the past year of 1 or more moder-
ate to severe attenuated positive symptoms (scores of 3–5 
on the SOPS 0–6 scale); (2) genetic risk and deterioration 
(GRD), defined as having a first-degree relative with an 
Axis I psychotic disorder or having an Axis II diagnosis 
of Schizotypal Personality Disorder and a 30% decline in 
functioning in the past year; or (3) Brief  intermittent psy-
chotic symptoms (BIPS), having 1 psychotic level symp-
tom (score of 6 on SOPS) that is brief  and spontaneously 
remits. CHR and HCs between the ages of 12–35 were 
eligible to participate.
Exclusion criteria for all participants included: (1) 
any Axis I  Schizophrenia-spectrum diagnosis; (2) non-
English speaking; (3) a medical or neurological disorder; 
(4) estimated IQ < 70; (5) significant head injury; or (6) 
severe substance abuse. HCs were additionally excluded 
if  they had a first-degree relative with a diagnosed Axis 
I psychotic disorder.
Because the Map task was introduced in Year 2 of the 
NAPLS study, a somewhat reduced sample completed the 
task, consisting of CHR: N = 609 and HC: N = 242 (see 
supplementary figure  1). All procedures were approved 
by the Institutional Review Board (IRB) at each site. 
Written informed consent (with assent from participants 
<18) was obtained from all participants.
The Map Task
The Map task was administered as part of a comprehen-
sive baseline assessment (see Addington38 for details). 
Participants were first read a set of instructions and then 
asked to complete specified errands by plotting their 
route on an 11 × 14  inch color map of a fictional town. 
The instructions contained specific details regarding how 
and in what order the errands needed to be completed, 
with emphasis placed on planning the most efficient 
route possible. Streets were displayed on the map that 
were lined with icons of businesses, offices and municipal 
buildings to simulate a typical town, including a hospital, 
various clothing and grocery stores, a post office, library, 
museum, firehouse, and apartments.
Participants were given a pen and instructed to draw 
the route on the map that they would take through town 
to complete the errands as efficiently and quickly as pos-
sible. Some errands could be completed at more than 1 
location giving the participant the opportunity to choose 
the best location, eg, which of 3 gas stations to go to. In 
addition, while there were sufficient choices for subjects to 
vary in efficiency, the instructions logically dictated when 
many of the errands should be completed. For example, 
participants were instructed to enter and exit the town via 
specific streets. After entering town and parking the car, 
the participant was expected to visit the bank to with-
draw money. Without money, none of the errands that 
followed could be completed.
The Map task generated 4 outcome indices: (1) 
Completion time; (2) Total blocks travelled; (3) Total tar-
get errands completed (out of 14 possible); and (4) Total 
errors. Errors resulted from: visiting an unnecessary loca-
tion; failure to use a door to enter or exit a location; incor-
rect use of a shortcut and for ordering errors. Ordering 
errors violated specific instructions and represented illog-
ical planning (eg, going to the Gas Station before getting 
one’s car from the Parking Lot, going shopping before 
withdrawing money at the Bank, visiting the Post Office 
before purchasing the card that had to be mailed).
In order to control for age-related change in perfor-
mance on the Map task, raw scores from each of the 4 
indices were transformed into standard Z-scores using 
the age-stratified means and SDs of the HC group. When 
applicable, indices were reverse-scored so that lower 
scores reflected worse performance relative to the HCs. 
An overall Map Capacity Score was calculated by aver-
aging the performance on errands, errors, and time. The 
overall Map composite was then re-standardized using 
the mean and SD of the HC group.
Clinical Measures
Axis I diagnoses were assessed by the Structured Clinical 
Interview for DSM-IV (SCID-I42). Prodromal symptoms 
were assessed by the Structured Interview for Prodromal 
Syndromes (SIPS) and the companion Scale of Prodromal 
Symptoms (SOPS39–41). Total scores for each subscale 
(positive, negative, disorganized, and general) were calcu-
lated. Total negative symptom scores were determined by 
adding items 2 through 5, excluding items 1 (social anhe-
donia) and 6 (deterioration in role) due to the overlap in 
the functioning measures. Social and role functioning 
was assessed using the GF:Social and GF:Role scales.8 
The GF:Social scale assesses peer relationships, peer con-
flict, age-appropriate intimate relationships, and involve-
ment with family members. The GF:Role scale rates 
performance and amount of support needed in one’s 
specific role (ie, school, work).8 The Global Assessment 
of Functioning Scale (GAF) assessed clinical symptoms, 
social and role functioning on one global scale.43
Statistical Analysis
All analyses were conducted using SPSS 16.0 (SPSS Inc). 
Comparisons of demographic and clinical characteristics 
were performed with Student’s t test for continuous vari-
ables and chi-square test for categorical variables.
The Spearman’s rho coefficient was used to determine 
the relationship between the Map task indices and demo-
graphic, clinical, and IQ measures. Group differences 
(CHR vs HC; Converter vs Non-Converter) were assessed 
with multivariate analysis of covariance (MANCOVA) 
with group as between subject factors and Map index 
scores (Blocks, Errors, Errands, Time) as within-sub-
ject factors, co-varying for baseline age, current and 
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premorbid IQ. Individual ANCOVAs were used to exam-
ine differences in the overall Map Capacity Score between 
the groups (CHR vs HC; Converter vs Non-Converter), 
co-varying for baseline age, current and premorbid IQ.
To determine whether the impairments on the Map task 
could predict conversion to psychosis, independent of the 
contributions of clinical symptoms, intellectual perfor-
mance, and role functioning (ie, achievement), a Cox pro-
portional hazards model was constructed with the Map 
Capacity Score, adjusting for baseline age, Total SIPS-
Positive, baseline GAF and GF:Role scores, and current 
and premorbid IQ scores. Bootstrap resampling with 
replacement (B = 10 000 samples) was used to internally 
validate the final prediction model.44 These analyses were 
conducted using data for those subjects who had either 
developed a psychotic disorder within the study period or 
who had been followed at least 24 months without devel-
oping psychotic symptoms. Missing data was imputed 
using mean values for Completion Time (missing 3 val-
ues) and IQ (missing 15 values) prior to use in all analyses.
Results
Sample Characteristics
Table  1 summarizes baseline demographic and clinical 
characteristics of the study sample. HC and CHR sub-
jects differed significantly on baseline age and years of 
education, but not on gender or race. The HC subjects 
were older and had more years of education and higher 
premorbid and current IQs than the CHR subjects. As 
expected, the CHR subjects reported higher scores on all 
of the SIPS subscales, and lower scores on the functioning 
measures than the HC subjects, indicating impairment.
At the time of testing, 61.1% of the CHR subjects that 
received the Map task were not receiving any medication, 
19.7% were receiving antipsychotics, 25.6% anti-depres-
sants, 6.9% anxiolytics, and 3.4% mood stabilizers. In addi-
tion, there was no relationship between medication type 
and performance on any of the Map task indices (rs < .10).
Map Task Group Comparison
Figure 1 displays the mean performance across the 4 Map 
indices for the CHR group, relative to the HCs. The CHR 
group showed significant impairments (P < .05) on all 4 
of the Map indices, with mild-to-moderate deficits seen on 
Blocks, Errands, and Completion Time and large impair-
ments on Errors (see supplementary table S1 for details). 
Baseline age was a significant covariate (F4, 845 = 9.69, P 
< .001).The CHR group also displayed a large impair-
ment on the overall Map Capacity Score (M  =  −0.73, 
SD = 1.83), indicating a general deficit on the task relative 
to the performance of HCs (M = 0.00, SD = 1.00).
Correlations Between Map Task Indices and 
Demographic, Clinical, and IQ Measures
In HC subjects, 3 Map task indices were significantly cor-
related with demographic and clinical measures as follows: 
(1) Blocks correlated with SIPS Negative total score; (2) 
Errors correlated with SIPS Negative total score, GF:Role 
Table 1. Baseline Demographic and Clinical Data and Statistics
Healthy Controls (N = 242) CHR (N = 609) t/χ2 P Value
Age, y 19.77 ± 4.80 18.55 ± 4.35 3.42 <.001
Education, y 12.67 ± 3.64 11.27 ± 2.83 5.35 <.001
Sex, N male (%) 126 (52.1) 352 (57.8) 2.31 .13
Race, N Caucasian (%) 133 (54.96) 352 (57.80) 0.570 .450
Premorbid IQ 108.30 ± 16.30 105.15 ± 16.56 2.50 .013
Current IQ 111.14 ± 14.03 103.83 ± 15.09 6.48 <.001
Scale of prodromal symptoms
 Positive 1.02 ± 1.63 11.94 ± 3.86 −57.90 <.001
 Negative 1.46 ± 2.30 11.83 ± 5.96 −36.44 <.001
 Disorganized 0.63 ± 1.17 5.16 ± 3.08 −30.88 <.001
 General 1.30 ± 2.16 9.25 ± 4.22 −35.90 <.001
GAF score 83.41 ± 10.76 48.38 ± 10.74 42.83 <.001
Global Functioning: Social Scale 8.87 ± 0.928 6.22 ± 1.54 30.61 <.001
Global Functioning: Role Scale 8.53 ± 1.39 5.97 ± 2.16 20.46 <.001
Baseline medicationa
 No medication — 372 (61.1) — —
 Anti-psychotics — 120 (19.7) — —
 Anti-depressants — 156 (25.6) — —
 Anxiolytic — 42 (6.9) — —
 Mood stabilizer — 21 (3.4) — —
Note: CHR, Clinical High-Risk; GAF, Global Assessment of Functioning Scale.
aFive CHR subjects were missing medication information for the baseline testing.
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and GAF score; and (3) Map Capacity Score significantly 
correlated with GF:Role (supplementary table S2).
In CHR subjects, the Map task indices significantly cor-
related with demographic and clinical measures as follows: 
(1) Blocks correlated GF:Role; (2) Errands correlated with 
GF:Role; (3) Errors correlated with SIPS Negative total 
score, GF:Role, and GAF score; (4) Completion time cor-
related with IQ; and (5) Map Capacity Score correlated 
with GF:Social and GF:Role and GAF score (supplemen-
tary table S3). IQ as measured by the WASI Vocabulary and 
Block Design subtests was correlated with Blocks, Errands, 
Errors, and the Map Capacity Score.
Prediction of Conversion to Psychosis
As shown in Figure 2, relative to the HCs, Converters and 
Non-Converters showed similar impairments on Blocks 
and Errands (P > .05). However, Converters showed large 
impairments on Errors (M = −1.01, SD = 1.97) and the 
Map Capacity Score (M  =  −1.38, SD  =  2.45; see sup-
plementary table S4 for more details) compared to the 
performance of Non-Converters (Errors: M  =  −0.35, 
SD = 1.00, Cohen’s d [effect size] = 0.35; Map Capacity 
Score: M = −0.57, SD = 1.63, Cohen’s d = 0.45). At a cut-
point of −0.5 SD, the Map Capacity Score has a Positive 
Predictive Value of 30%, Negative Predictive Value of 
81%, sensitivity of 50% and a specificity of 64%.
The Map Capacity Score significantly predicted con-
version to psychosis (Overall model χ2 = 23.59, df = 2, 
P < .001). As shown in table 2, even when adjusting for 
baseline age, Total SIPS-Positive, baseline GAF and 
GF:Role scores, and current and premorbid IQ scores 
the Map Capacity Score continued to predict conver-
sion to psychosis. The bootstrap approximation with 10 
000 iterations yielded bias-corrected and accelerated CIs, 
which demonstrated the robustness of the Map Capacity 
Score to predict psychosis because zero is not between the 
lower and upper bound (Map Capacity Score: 95% CI: 
(−0.416) to (−0.061), P = .009; Age: 95% CI: (−0.107) to 
(−0.004), P  =  .12; Positive Symptoms: 95% CI: (0.046) 
to (0.187), P = .001; GAF: 95% CI: (−0.028) to (0.024), 
P  =  .93; Current IQ: 95% CI: (−0.024) to (0.014), 
P  =  .594; Premorbid IQ: 95% CI: (−0.005) to (0.033), 
P = .14; GF:Role: 95% CI: (−0.199) to (0.054), P = .257).
Discussion
To the best of our knowledge, the Map task is one of the 
first laboratory measures specifically designed to assess a 
young person’s basic capacity to function in society, ie, to 
measure capacity to carry-out age-appropriate skills that 
lead to independent community living. From this perspec-
tive capacity provides the foundation for what can actu-
ally be achieved. This is comparable to the comparison 
between IQ (capacity) vs grades at school (achievement). 
In terms of applications to high-risk populations and 
early interventions, this study yielded 3 main findings. 
First, CHRs, in general, performed poorly on the task 
relative to HCs. Second, CHR individuals who later devel-
oped psychosis were more impaired on several aspects of 
the task when compared to subjects who did not develop 
psychosis, suggesting that functional capacity may serve 
as a marker of impending psychosis. Lastly, and especially 
important to supporting marker potential, performance 
on the Map task was predictive of conversion to psycho-
sis, independent of intellectual deficits, clinical symptoms, 
and role achievement. This suggests that functional capac-
ity may represent a basic biologically-based trait that has 
the potential to predict psychosis.
Overall, the Map task was effective in differentiating 
CHR subjects, in general, from HCs, with the CHR group 
scoring significantly lower than the HC group on sev-
eral the Map task indices, suggesting capacity problems 
Fig. 1. Map task performance (z-score ± SEM) of the Clinical 
High-Risk group relative to the Healthy Control (HC) group 
(mean set to 0, SD set to 1). Note: +P = .05; *P < .05; **P < .01; 
***P < .001. Dotted line represents performance of HC group.
Fig. 2. Map task performance (z-score ± SEM) for Clinical High-
Risk (CHR) Converters vs CHR Non-Converters. Note: *P < .05; 
**P < .01. ***P < .001.
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are characteristics of risk for psychosis. CHR subjects 
made mistakes on simple instructions, such as entering 
or exiting the town using the wrong street, entering extra 
stores not on the list, and not entering/exiting the stores 
through the indicated door. The overall Capacity Score, 
which takes into account 3 of the major Map task indi-
ces, indicates a general deficiency of functional capacity 
in the CHR group that may be comparable to a general 
index of impaired neurocognitive performance.
Of perhaps more importance, the Map Capacity Score 
significantly predicted conversion to psychosis, above and 
beyond the contributions of baseline attenuated posi-
tive symptoms. In addition, this relationship was not an 
artifact of IQ deficits or clinical symptoms, as the Map 
Capacity Score predicted psychosis even when controlling 
for intellectual performance. Of particular interest, while 
CHR Converters showed similar performance on hits, ie, 
Errands, compared to Non-Converters, they made signifi-
cantly more Errors. This suggests that the Map task taps 
into a specific domain of real-life functioning, the ability 
to stay on target and screen out irrelevant stimuli/tasks. 
Past work from our group has shown that true-positive 
individuals (ie, Converters) consistently have lower social 
functioning and lower, but inconsistent, role achievement 
scores, as measured in several populations using the GF 
scales, relative to Non-Converters many years before onset 
of psychosis.8 The current study extends these findings by 
indicating that true-positive subjects have a larger deficit 
in their “capacity” to perform everyday tasks and that this 
separate dimension of functioning may serve, in its own 
right, as an early developmental marker of eventual illness.
This is the first prodromal study, to our knowledge, to 
focus on the capacity of role functioning as being distinctly 
different than social skills, where role represents a broader 
adjustment to life demands than just school or work per-
formance. Moreover, our findings indicate that efficient 
functioning in a real-world situation, while depending on 
cognition/IQ, may also involve a broader skill set. Measures 
such as the Map are “neurofunctional,” as they involve a 
substantial neurocognitive component, but are measuring 
skill sets critical for carrying out everyday activities, such 
as taking the bus to school, going to a restaurant, getting 
a driver’s license, or in the case of the Map task, carrying 
out a shopping trip. While these tasks involve IQ, work-
ing memory, declarative memory, processing speed, etc., 
functional capacity can be considered midway between 
complex real-world behaviors and the more reductionis-
tic cognitive building blocks. Along this progression from 
cognition→capacity→achievement, achievement is multi-
determined and subject to considerable environmental 
input and thus difficult to assess, while capacity is closer 
to biological and genetic causation. These vulnerability or 
risk factors are comparable to neurocognitive risk factors 
but are tapping a different domain of impairment involv-
ing more complex behaviors than cognitive processes. For 
example, if an individual wants to go to a restaurant, the 
ability to plan this event, obtain the reservations, and orga-
nize the trip, would all be capacity; going to the restaurant 
would be the achievement.
Overall, this preliminary assessment of  the Map task 
provides encouraging results for the widespread use of 
this measure in prodromal research. There was virtually 
no relationship between Map indices and clinical symp-
toms in the CHR group, supporting the assertion that 
ability to perform at school or work are problems that 
are not determined by positive symptoms.15 In contrast, 
the Map Capacity Score was significantly correlated 
with role achievement,8 at comparable levels to correla-
tions reported between the UPSA and other measures 
of  global functioning such as the GAF.45 Ideally, a mea-
sure of  functional capacity would test skills in an actual 
real-world situation or setting (ie, at a grocery store46). 
However, practical and logistical issues limit the abil-
ity to utilize a real-world setting. Moreover, current 
functional capacity measures are typically designed to 
assess skills that are more relevant for an adult popula-
tion, such as writing a check,30 which can be particularly 
problematic for CHR research that involves adolescents 
and young adults. The Map task circumvents some of 
these issues by recreating an age-appropriate experience 
of  planning and carrying out a series of  errands. The 
current findings suggest that the Map task is sufficiently 
Table 2. Predicting Conversion to Psychosis With the Map Capacity Score
Conversion to Psychosis
β SE Wald Hazard Ratio (95% CI) P Value
Map Capacity Score −.23 0.10 5.436 0.792 (0.650–0.963) .02
Baseline age −.05 0.03 1.928 0.956 (0.897–1.019) .165
SIPS total positive .11 0.03 11.179 1.116 (1.047–1.191) .001
Global Assessment of Functioning −.001 0.01 0.007 0.999 (0.973–1.025) .932
Current IQ −.01 0.01 0.234 0.995 (0.976–1.015) .629
Premorbid IQ .01 0.01 2.071 1.013 (0.995–1.031) .15
GF: Role −.07 0.07 1.185 0.930 (0.815–1.06) .276
Note: SIPS, Structured Interview for Prodromal Syndromes; GF, Global Functioning.
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challenging for healthy adolescent populations, elimi-
nating the possibility of  ceiling effects on performance, 
and is sensitive enough to differentiate between clinical 
and healthy populations. Of  the indices generated by the 
Map task, as indicated above, errors are most informa-
tive. It should be noted that based on the current find-
ings scoring of  the blocks travelled has been eliminated 
from the standard Map administration since it proved to 
be very labor intensive and did not differentiate between 
any of  the CHR groups.
In conclusion, the Map task adds to the newly emerg-
ing set of  measures of  functional capacity, a construct 
gaining attention as critical to the etiology of  psychosis 
and therefore to prevention. Our findings have extended 
this notion to the early stages of  the illness and suggest 
that functional capacity is primary to achievement in the 
real-world and therefore may constitute a new marker of 
impending illness. Future research should examine the 
potential of  a multi-variable functional profile consist-
ing of  a range of  capacity and achievement measures to 
provide the most accurate method to predict long-term 
prognosis. In turn, the complexity of  functional deficits 
is likely to contribute unique information for developing 
more optimal preventive interventions.
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